Inari Medical, INC Form 4 insider transactions
Director William Hoffman sold 40,000 shares of Inari Medical (NARI) common stock on October 29, 2024, under a pre-arranged 10b5-1 trading plan.
Director William Hoffman of Inari Medical, Inc. executed sales of common stock on October 16, 2024, under a pre-arranged Rule 10b5-1 trading plan.
Kevin T. Strange, CFO of Inari Medical, reports acquisition of restricted stock units and disposition of shares to cover tax obligations.
Thomas Tu, Chief Medical Officer of Inari Medical, reports the disposal of common stock to cover tax obligations related to vesting restricted share units.
Andrew Hykes, President and CEO of Inari Medical, reports changes in beneficial ownership due to tax obligations related to vesting restricted share units.
Director William Hoffman reports disposition of Inari Medical common stock to cover tax obligations related to vesting restricted share units.
Mitch C. Hill, CFO of Inari Medical, Inc., reported the disposal of common stock to cover tax obligations related to vesting restricted share units.
Director William Hoffman of Inari Medical, Inc. sold shares of common stock on September 16, 2024, under a pre-arranged Rule 10b5-1 trading plan.
Inari Medical's CFO, Mitch C. Hill, exercised stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan.
Inari Medical's CEO, Andrew Hykes, sold 3,000 shares of common stock at $50 per share under a pre-arranged 10b5-1 trading plan.
Director William Hoffman of Inari Medical, Inc. reports selling shares of common stock in multiple transactions between August 16 and August 19, 2024, under a pre-arranged trading plan.
Inari Medical's CFO, Mitch C. Hill, executed stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.
Inari Medical's CEO, Andrew Hykes, sold 3,000 shares of common stock at an average price of $55.23, executed under a pre-arranged Rule 10b5-1 trading plan.
Director William Hoffman of Inari Medical, Inc. executed multiple sales of common stock on July 16, 2024, under a pre-arranged Rule 10b5-1 trading plan.
Thomas Tu, Chief Medical Officer of Inari Medical, Inc., reported the sale of 3,480 shares of common stock on July 16, 2024, under a pre-arranged Rule 10b5-1 trading plan.
Thomas Tu, Chief Medical Officer of Inari Medical, Inc., sold a portion of his holdings in common stock on July 15, 2024, under a pre-arranged 10b5-1 trading plan.
Inari Medical's CFO, Mitch C. Hill, exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.
Director William Hoffman sold 20,000 shares of Inari Medical (NARI) common stock at an average price of $50.15, while also having shares withheld to cover tax obligations related to vesting restricted share units.
Andrew Hykes, CEO of Inari Medical, reports a sale of 3,000 shares and several transactions related to tax obligations from vesting restricted share units.
Mitch C. Hill, CFO of Inari Medical, reports the disposal of common stock to cover tax obligations related to vesting restricted share units.
Form 4: Inari Medical's Chief Medical Officer, Thomas Tu, Reports Stock Disposals to Cover Tax Obligations
Thomas Tu, Chief Medical Officer of Inari Medical, reported the disposal of common stock to cover tax obligations related to vesting restricted share units.
Director Rebecca Chambers sold 260 shares of Inari Medical (NARI) at $45.99 per share on June 21, 2024, under a pre-arranged 10b5-1 trading plan.
Director William Hoffman sold shares of Inari Medical (NARI) on June 17, 2024, under a pre-arranged 10b5-1 trading plan.
Inari Medical's CFO, Mitch C. Hill, exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.
Director Robert Warner amends a previous Form 4 filing to include a Power of Attorney, related to restricted stock units.
Catherine Szyman, a director at Inari Medical, amended her Form 4 filing to include a Power of Attorney, related to restricted stock units granted on April 24, 2024.
Jonathan Root, a director at Inari Medical, amends his Form 4 filing to include a previously granted Power of Attorney.
Donald Milder, a director at Inari Medical, amends a previous Form 4 filing to include a Power of Attorney, while also reporting recent transactions in Inari Medical stock held indirectly through a trust.
Dana G. Mead, Jr., a director at Inari Medical, Inc., amended his Form 4 filing to include a Power of Attorney, related to restricted stock units.
Cynthia Lucchese, a director at Inari Medical, amended her Form 4 filing to include a previously granted Power of Attorney.